RPTX

Repare Therapeutics Inc. (RPTX) Economic Moat Analysis (2026)

Invetso Score: 2.2/10 — Weak · Last Updated: 2026-09-01

Monthly Update

No material changes this month.

Intangible Assets

Score: 2.2 (Weak)

RPTX shows no evident durable brand, patent, or regulatory franchise in the provided data, so it lacks the kind of protected pricing power that stronger peers use to sustain margins.

Negative TTM ROIC and ROCE indicate the business is not converting any presumed intangible advantage into economic returns, unlike peers with defensible IP or licensed positions.

The absence of disclosed long-run margin or return history in the supplied metrics limits evidence of persistent customer willingness to pay a premium versus peers.

Any intangible asset base appears weakly monetized relative to peers because low asset productivity suggests customers can substitute alternatives without meaningful penalty.

Switching Costs

Score:

The provided metrics do not show retention-linked economics, and negative ROIC implies customers are not locked in by high switching frictions that would protect returns.

A cash conversion cycle of -12.8 days reflects working-capital efficiency, but it does not by itself indicate customer lock-in or contractual switching costs versus peers.

No evidence is provided of embedded workflows, data migration barriers, or compliance dependencies that would make replacement costly for customers relative to peers.

If switching costs were material, they would عادة support positive and durable returns, yet the current profitability profile suggests limited pricing power from retention.

Network Effects

Score:

The supplied data contains no sign of user, data, or ecosystem feedback loops that would compound value over time versus peers.

Negative ROIC and very low asset turnover are inconsistent with a platform-like model where each additional participant strengthens the franchise and improves economics.

No evidence is provided that customers depend on RPTX for core industry functionality, so any network effect appears absent or immaterial relative to stronger peers.

Without observable cross-side or data-network reinforcement, the business does not show the self-reinforcing moat layer needed for durable superiority.

Cost Advantage

Score:

Asset turnover of 0.09x indicates very low revenue generation per unit of asset base, which argues against a structural cost advantage versus more efficient peers.

Negative ROIC and ROCE suggest operating economics are not superior enough to translate into lower unit costs or better spread capture than competitors.

The provided metrics do not show scale-driven procurement, manufacturing, or distribution advantages that would lower costs relative to peers.

A working-capital benefit alone is not a durable cost moat because it can be replicated by peers and does not necessarily improve long-run pricing power.

Efficient Scale

Score:

The data does not indicate that RPTX operates in a naturally concentrated niche where limited demand can support a durable local monopoly versus peers.

Negative returns imply the company is not currently earning excess profits that would typically accompany efficient-scale protection from competition.

No evidence is provided that the market structure prevents entry or that incumbency creates a persistent advantage in serving a finite customer base.

Compared with peers that benefit from regulated, capacity-constrained, or highly localized markets, RPTX shows no clear efficient-scale barrier.

Overall Score

Score:

RPTX appears to have a weak moat versus peers because the supplied metrics show negative capital returns, very low asset productivity, and no evidence of durable switching costs, network effects, or protected intangible assets; the only visible efficiency signal is working-capital management, which is not a structural advantage.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Repare Therapeutics Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →